Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Terminated 2Completed 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Tumor-Agnostic 1Other hematologic neoplasm 1

Conditions

Recurrence 1Neoplasms 1Neoplasm Metastasis 1Leukemia, Myeloid, Acute 1Leukemia 1

Interventions

Cyclophosphamide 1492Cisplatin 1413Paclitaxel 1316Radiotherapy 1261Carboplatin 1249Gemcitabine 1215Docetaxel 1109Bevacizumab 1030Fluorouracil 894Doxorubicin 792Dexamethasone 748Rituximab 719Capecitabine 716Oxaliplatin 700Etoposide 678pembrolizumab 677Irinotecan 634Filgrastim 621Cytarabine 586Leucovorin 579Nivolumab 558Vincristine 515Prednisone 475Cetuximab 465Bortezomib 459Erlotinib Hydrochloride 456Trastuzumab 447Methotrexate 438Lenalidomide 427Pemetrexed 419

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × Interventional × LY2510924 × Clear all
NCT02652871 2019-11-15

LY2510924, Idarubicin and Cytarabine in Patients With Relapsed or Refractory Acute Myeloid Leukemia

M.D. Anderson Cancer Center

Phase 1 Completed
36 enrolled
Other hematologic neoplasm

Leukemia, Recurrence, Leukemia, Myeloid, Acute

NCT01439568 2019-07-23

A Study of LY2510924 in Participants With Extensive-Stage Small Cell Lung Carcinoma

Eli Lilly and Company

Phase 2 Completed
90 enrolled 13 charts
Tumor-Agnostic

Neoplasm Metastasis, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡